Anti-interleukin-11 antibodies and methods of use thereof
AssigneeBoehringer Ingelheim International GmbH
InventorsAnita Bloching, Maureen Crames, Pankaj Gupta, Julie Jia Li Hawkins, Stefan Hoerer, Siqi Lin, Michael S. Marlow
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to anti-interleukin-11 (IL-11) antibodies and antigen-binding fragments thereof including their use in the treatment or prevention of an IL-11 (interleukin 11) pathway disease or disorder.
Claims26
1-60. (canceled)
An anti-interleukin-11 (IL-11) antibody or an antigen-binding fragment thereof comprising:
- a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1), the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2), and the amino acid sequence of SEQ ID NO:
- 4 (H-CDR3), or 5 (H-CDR3);
- and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 8 (L-CDR1), the amino acid sequence of SEQ ID NO:
- 11 (L-CDR2), and the amino acid sequence of SEQ ID NO:
- 12 (L-CDR3).
An anti-interleukin-11 (IL-11) antibody or an antigen-binding fragment thereof comprising:
- (i) (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1), the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2), and the amino acid sequence of SEQ ID NO:
- 5 (H-CDR3);
- and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 8 (L-CDR1), the amino acid sequence of SEQ ID NO:
- 11 (L-CDR2), and the amino acid sequence of SEQ ID NO:
- 12 (L-CDR3);
- or
- (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 14, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 23;
- or
- (c) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 27, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 36;
- or
- (ii) (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1), the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2), and the amino acid sequence of SEQ ID NO:
- 5 (H-CDR3);
- and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 8 (L-CDR1), the amino acid sequence of SEQ ID NO:
- 11 (L-CDR2), and the amino acid sequence of SEQ ID NO:
- 12 (L-CDR3);
- or
- (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 15, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 23;
- or
- (c) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 28, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 36;
- or
- (iii) (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1), the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2), and the amino acid sequence of SEQ ID NO:
- 5 (H-CDR3);
- and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 8 (L-CDR1), the amino acid sequence of SEQ ID NO:
- 11 (L-CDR2), and the amino acid sequence of SEQ ID NO:
- 12 (L-CDR3);
- or
- (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 16, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 23;
- or
- (c) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 29, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 36;
- or
- (iv) (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 1 (H-CDR1), the amino acid sequence of SEQ ID NO:
- 2 (H-CDR2), and the amino acid sequence of SEQ ID NO:
- 4 (H-CDR3);
- and
- a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 8 (L-CDR1), the amino acid sequence of SEQ ID NO:
- 11 (L-CDR2), and the amino acid sequence of SEQ ID NO:
- 12 (L-CDR3);
- or
- (b) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 17, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 23;
- or
- (c) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 30, and a light chain comprising the amino acid sequence of SEQ ID NO:
- 36.
An anti-human IL-11 antibody or antigen-binding fragment, wherein when bound to human IL-11, the antibody or antigen-binding fragment binds to amino acid residues R15, D19, L23, R26, S27 L29, A30, D31, R33, R40, N50, L57, A58, R111, H161, L162, D165, W166, V168, R169, L172, L173, K175, or T176 as set forth in SEQ ID NO:
- 51, and wherein the antibody blocks binding of IL-11 to IL-11Rα, and wherein the antibody bind to human IL-11 with a high affinity (e.g., 100 pM or less).
Dependencies are inferred from the claim text.